This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy Of Synthetic Biologics, Inc.

Stocks in this article: SYN

ROCKVILLE, Md., Aug. 6, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Lewis (Lew) Barrett joined the Company as its Senior Vice President, Commercial Strategy. Mr. Barrett, former Assistant Vice President, Established Products at Pfizer and Vice President Global Business Manager, Infectious Diseases at Wyeth Pharmaceuticals, brings his expertise in the development, commercialization and launch of infectious disease product candidates to the Synthetic Biologics' team.

As the senior marketing executive, Mr. Barrett successfully led, co-chaired or served on teams that focused on infectious diseases, oncology, transplantation, and hemophilia during his 25-year career at Wyeth (acquired by Pfizer in 2009). He brings to Synthetic Biologics his expertise in U.S. and global strategy, branding, clinical development, medical affairs, supply chain, business development and strategic alliance management. Mr. Barrett was instrumental in building the brand and led global commercialization efforts for Wyeth's in-line IV antibiotic, Zosyn®/Tazocin® (the second IV antibiotic to achieve $1 billion+ in sales), and managed the U.S. launch of Wyeth's broad-spectrum IV antibiotic, Tygacil®.

Prior to joining Synthetic Biologics as Senior Vice President, Commercial Strategy, Mr. Barrett served as an advisor to the Company since September 2012. Utilizing his depth of experience in the anti-infective, hospital and biopharma fields, Mr. Barrett provides strategic consultation to the global life sciences field with a particular focus on brand strategy, lifecycle strategy, business development, and strategic communications through LL Barrett Biopharmaceutical Consulting, LLC.

Mr. Barrett earned an M.B.A. from Temple University and a B.S. degree in Biology from Stockton State College.

"We are pleased to welcome Lew to the Synthetic Biologics' team and expect that his extensive experience in the development and commercialization of anti-infectives will be vital to the Company as we develop SYN-004 for the prevention of C. difficile infections and monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections," stated Jeffrey Riley, Chief Executive Officer at Synthetic Biologics.

"We recently initiated the manufacturing process for our lead infectious disease candidate, SYN-004, intended to prevent the devastating effects of C. difficile infections, for which there is currently no vaccine or other approved preventive therapy. We look forward to benefiting from Lew's knowledge and big pharma experience for our C. difficile program as well as the other programs in our infectious disease pipeline," concluded Mr. Riley.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.

Zosyn®, Tazocin® and Tygacil® are registered trademarks of Pfizer or its affiliates.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs